My mission in life is to help others succeed
Serving NJ since 2006
+1 234 056 78 90

Blog

  1. Homepage
  2. Blog
image credit everdayhealth.com
Diagnostic Laboratory Services

Unveiling the Promise of Multi-Cancer Early Detection (MCED) Tests: Revolutionizing Cancer Diagnosis

|

Introduction: Cancer detection has entered a new era with the advent of Multi-Cancer Early Detection (MCED) tests. These revolutionary “liquid biopsy” tests analyze a blood sample to identify specific biological signals released by cancer cells. In this article, we’ll delve into the significance of MCED tests, their potential to detect multiple cancer types from a single blood sample, and the ongoing research supporting their development.

Decoding Multi-Cancer Early Detection (MCED) Tests: MCED tests represent a groundbreaking leap in cancer detection. Unlike traditional single-target cancer screenings, MCED tests aim to identify various cancer types using a single blood sample. By analyzing specific pieces of DNA or proteins from cancer cells in the blood, MCED tests offer the potential to not only diagnose cancer but also pinpoint the organ of origin. Some MCED tests focus on identifying the likelihood of cancer presence, necessitating further imaging tests to locate the source of abnormal DNA or proteins.

The Underlying Promise: Early Detection:

  1. Enhanced Survival Rates: Timely cancer detection is correlated with improved survival rates and more effective treatment outcomes.Reduced Invasiveness: MCED tests may reduce the need for invasive procedures like biopsies, minimizing patient discomfort and risk.Tailored Treatments: Early diagnosis via MCED enables personalized treatment strategies based on individual cancer profiles.

Why Pursue MCED Tests? The majority of cancer-related deaths stem from cancers lacking proven early detection methods. MCED tests aim to address this gap by potentially identifying a wide range of cancers before symptoms manifest.

MCED Tests’ Regulatory Status and Current Use: MCED tests are not yet FDA approved, but some operate under Clinical Laboratory Improvement Act (CLIA) regulations as lab-developed tests, allowing their use based on medical orders. Ongoing data collection by test developers aims for eventual FDA approval.

Supplementing Existing Screening Methods: MCED tests are positioned to complement rather than replace current screening tests like mammograms, Pap tests, colonoscopies, and PSA blood tests. They may extend the spectrum of detectable cancers, especially those without established screening protocols.

Unanswered Questions and Ongoing Research: Several crucial questions surround MCED tests:

  1. Detection Accuracy: The accuracy of MCED tests for various cancers and their subtypes remains a subject of ongoing investigation.Time Gains in Early Detection: MCED tests must identify cancers significantly earlier than symptom onset to positively impact treatment outcomes.Impact on Outcomes: Research must confirm whether earlier detection via MCED translates to improved patient outcomes and reduced cancer-related mortality.False Positives and Negatives: Addressing the prevalence of false-positive and false-negative results remains essential for patient well-being.Target Population and Frequency: Determining who should undergo MCED tests and the optimal testing intervals requires careful consideration.

American Cancer Society’s Role: The American Cancer Society (ACS) plays a pivotal role in advancing MCED science:

  • Research: ACS funds research and collaborates with MCED test developers to provide insights and assess test accuracy within population studies.Advocacy: Once an MCED test proves effective and gains FDA approval, ACS advocates for equitable access to this test for recommended individuals.

The GRAIL Galleri Test in Focus: The GRAIL Galleri test, currently not FDA approved but available under CLIA waivers, exemplifies the MCED landscape. This central laboratory test is prescribed by doctors, with costs often borne by patients. Ongoing large-scale clinical trials aim to address uncertainties surrounding its accuracy and capabilities.

Conclusion: Multi-Cancer Early Detection (MCED) tests hold the potential to transform cancer diagnosis and management. While not yet FDA approved, these tests signify a promising advancement in detecting a spectrum of cancers at early stages. With ongoing research and collaborations, MCED tests could bridge the gap in early detection for numerous cancers, ultimately saving lives and altering the trajectory of cancer care.

Disclaimer: The information in this article is based on the American Cancer Society’s medical and editorial content team’s insights as of September 2021. Subsequent developments may have occurred. For the latest updates, refer to reputable sources and ongoing research.

About: Sunrise Group of Companies, encompassing Sunrise Clinical Labs, Sunrise Diagnostic Laboratory, Sunrise Care, Sunrise Clinical Services, and the Sunrise Second Chance Foundation, showcases a commitment to comprehensive care and support. Notably, Sunrise Clinical Services stands as a beacon of hope for Substance Use Disorder, while the Sunrise Clinical and Diagnostic Laboratories serve as reference labs specializing in infectious diseases and toxicology screening, offering confirmatory testing.

Read more

Navigating the COVID-19 Landscape: Insights from a Reference Lab with Extensive Testing Experience

|

In the face of escalating COVID-19 cases, the global community finds itself at a critical juncture, grappling with emerging variants and renewed challenges. As a reference lab with a wealth of experience in conducting COVID-19 testing throughout the pandemic, we are acutely aware of the concerns surrounding the current situation. With the appearance of the new BA.2.86 variant and ongoing rises in cases, understanding what to look for in the new variants and when to get tested remains crucial for effective management.

BA.2.86, a distant relative of the omicron variant, has garnered attention due to its unique mutations on the spike protein. While it is still early to definitively assess the strain’s impact, health agencies worldwide are closely monitoring its behavior. The large number of mutations it carries raises questions about potential changes in transmissibility, immune evasion, and diagnostic accuracy.

The CDC’s recent risk assessment (Aug. 23) offers initial insights into BA.2.86. According to the assessment, existing tests and medications continue to hold promise in detecting and treating this variant. Nonetheless, it is noted that BA.2.86 might exhibit increased infectivity among individuals with prior immunity. The assessment also reassures that there is no current evidence suggesting heightened disease severity linked to this variant. The fluid nature of this situation is well-captured by the CDC’s statement, “That assessment may change as additional scientific data are developed. CDC will share more as we know more.”

The rise in COVID-19 hospital admissions, particularly driven by offshoots like EG.5 and FL.1.5.1, underscores the urgency of vigilance. While summer festivities bring joy and social connection, the lack of widespread mask usage and growing gatherings have facilitated a fresh surge in cases. This situation mandates a reevaluation of preventative measures.

In the words of Mohammed Naeem, founder and CEO of the Sunrise Group of companies, “Prevention remains our most powerful tool in combating the spread of COVID-19 and its variants. As we navigate through this evolving landscape, it’s imperative that individuals take proactive steps to protect themselves and their communities.” Naeem’s sentiment reflects the collective responsibility we all share in curbing the virus’s reach.

As a reference lab committed to public health, we offer the following recommendations:

– Stay Informed: Regularly monitor updates from reputable health organizations like the CDC and WHO to stay abreast of the latest developments.
– Adhere to Guidelines: Follow recommended guidelines, including mask usage and social distancing, especially in crowded or indoor settings.
– Prioritize Testing: If you experience COVID-19 symptoms, have been exposed to a confirmed case, or are returning from high-risk areas, seek testing promptly.
– Maintain Hygiene Practices: Regular handwashing and proper respiratory etiquette remain essential in curbing transmission.
–Consider Vaccination and Boosters: Vaccination continues to play a pivotal role in reducing severe illness. – Stay informed about booster dose recommendations.
– Adjust Travel Plans: If planning to travel, research your destination’s COVID-19 situation and any entry requirements. Consider postponing non-essential trips if the situation warrants.
– Practice Flexibility: Be prepared for evolving guidance as scientists learn more about emerging variants.

In conclusion, as we confront the BA.2.86 variant and surges in cases, it is paramount that we remain vigilant, adaptable, and committed to collective well-being. By staying informed, adhering to guidelines, and acting responsibly, we can collectively navigate this challenging phase and emerge stronger.

About: Sunrise Group of Companies, encompassing Sunrise Clinical Labs, Sunrise Diagnostic Laboratory, Sunrise Care, Sunrise Clinical Services, and the Sunrise Second Chance Foundation, showcases a commitment to comprehensive care and support. Notably, Sunrise Clinical Services stands as a beacon of hope for Substance Use Disorder, while the Sunrise Clinical and Diagnostic Laboratories serve as reference labs specializing in infectious diseases and toxicology screening, offering confirmatory testing.

Read more
News

Mohammed Naeem Honored for Remarkable Healthcare and Philanthropic Contributions

|

FOR IMMEDIATE RELEASE

Mohammed Naeem, Founder and CEO of Sunrise Group of Companies, Honored for Remarkable Healthcare and Philanthropic Contributions

New York, June 29, 2023 – Mohammed Naeem, visionary Founder and CEO of the Sunrise Group of Companies, was recognized today at a ceremony held at the New York City Police Headquarters, 1 Police Plaza, New York, NY. The award, presented by First Deputy Commissioner Edward Caban, celebrates Mr. Naeem’s outstanding achievements and unwavering dedication to the fields of healthcare and philanthropy.

Mohammed Naeem’s relentless pursuit of excellence has transformed the landscape of healthcare and philanthropy, making an indelible mark on the lives of countless individuals. With innovation at the heart of his endeavors, Mr. Naeem has spearheaded initiatives that reflect the core values of compassionate care and community service.

Under his leadership, the Sunrise Group has emerged as a beacon of holistic healing, revolutionizing addiction treatment, mental health support, and diagnostic services through its portfolio of companies. The innovative wrap-around services philosophy championed by Mr. Naeem has redefined patient care, focusing on all-encompassing well-being and fostering a sense of belonging within the community.

Beyond his remarkable contributions to healthcare, Mr. Naeem’s philanthropic efforts have touched myriad lives. His philosophy of “paying it forward” has translated into concrete action, supporting vital causes such as cancer research, education programs, and assistance for survivors of domestic violence. This ethos of selfless service has not only enriched lives but also ignited a wave of positive change within the community.

First Deputy Commissioner Edward Caban, while presenting the award, praised Mohammed Naeem for his exceptional dedication to improving lives and serving as a role model for others to follow. He stated, “We are proud to honor Mr. Naeem for his tireless commitment to healthcare innovation and community upliftment. His impact resonates far beyond the boundaries of our great city, embodying the spirit of unity, service, and progress.”

In his acceptance response, Mohammed Naeem expressed his gratitude for the recognition and dedicated the award to the Sunrise Group team, supporters, and the communities that the organization serves. He reiterated his commitment to advancing healthcare, philanthropy, and community empowerment, reaffirming his belief in the transformative power of collective effort.

The ceremony concluded with a sense of optimism and renewed determination to emulate Mohammed Naeem’s example of dedicated service and impactful contributions. His legacy will continue to inspire generations to come, leaving an indelible imprint on the fabric of healthcare and community engagement.

For media inquiries, please contact: Anwer Qureishi, aqureishi@sunrisegoc.com or via Phone Number 973-444-1772.

About Mohammed Naeem and Sunrise Group of Companies:

Mohammed Naeem is the Founder and CEO of the Sunrise Group of Companies, a dynamic conglomerate committed to healthcare and philanthropic initiatives. His innovative approach to patient care and community service has garnered accolades and transformed lives, embodying the spirit of positive change.

Website: www.MohammedNaeem.org  LinkedIn  https://www.linkedin.com/in/mohammed-naeem-sunrise/ Instagram @mrmohammednaeem Twitter @_mohammednaeem Facebook https://www.facebook.com/mohammad.naeem.547

Read more

Combating the Silent Threat: Illegal Fentanyl Usage and How Sunrise Clinical Services Can Make a Difference

|

Introduction: As National Fentanyl Prevention & Awareness Day on August 21 approaches, the gravity of the situation cannot be understated. Illegally made fentanyl, a synthetic opioid, has entrenched itself as a looming danger in the United States, contributing to countless fatal drug overdoses. With nearly 200 lives lost each day due to overdoses related to synthetic opioids such as illegal fentanyl, it’s crucial that we delve into the severity of this crisis and understand the dangers it poses.

Mr. Mohammed Naeem, CEO of Sunrise Clinical Services, states: “At Sunrise Clinical Services, our commitment to tackling opioid addiction is unwavering. We understand the urgency of addressing the fentanyl crisis and its profound impact on individuals and communities. Through comprehensive diagnosis, prevention, and treatment initiatives, we aim to provide a beacon of hope to those affected by this epidemic.”

The Rising Threat: Fentanyl, originally designed for medical use, has infiltrated the illegal drug market with catastrophic consequences. Its potency is so intense that even a minuscule amount can result in fatal overdoses. The illegal production and distribution of fentanyl have exacerbated the opioid crisis, leaving devastation in their wake.

The Lethal Effects: While fentanyl offers an alluring and intense high, its dangers are unparalleled. The risk of overdose is alarmingly high due to its potency. Often unbeknownst to users, fentanyl-laced drugs lead to unintentional overdoses. A slight dosage miscalculation can be fatal, as fentanyl suppresses the respiratory system, causing respiratory failure and death.

A Grim Statistic: The harsh reality is that nearly 200 lives are lost daily in the United States due to overdoses related to synthetic opioids like illegally made fentanyl. Behind these staggering figures are individuals, each with aspirations, families, and potential, tragically cut short by a substance that shows no mercy. The impact of these losses reverberates far beyond the individual, affecting families, friends, and entire communities.

The Need for Awareness and Prevention: National Fentanyl Prevention & Awareness Day is a poignant reminder that a united front is necessary to tackle this crisis. Awareness is the first step towards prevention. Educating ourselves and our loved ones about the dangers of illegally made fentanyl empowers us to make informed decisions. Communities, healthcare professionals, law enforcement, and policymakers must collaborate to address the root causes of the fentanyl epidemic.

Seeking Help and Support: For those grappling with substance abuse, remember that assistance is available. Turn to addiction treatment centers, support groups, and medical professionals who can offer guidance and support in the path to recovery.

Conclusion: As we commemorate National Fentanyl Prevention & Awareness Day on August 21, let us remember the lives lost to illegal fentanyl usage and renew our commitment to preventing further tragedies. The fight against this silent menace requires awareness, education, and collective action to counter its devastating effects on our society. By joining forces, we can create a safer, healthier future for all.

Read more
Press Releases

Sunrise Second Chance Foundation Founder Recognized for Community Service

|

June 1, 2018 9:00 AM EDT

Irvington, N.J., Founder and Chairman of Sunrise Second Chance Foundation Mr. Mohammad Naeem received a distinguished Community Service Award in recognition of his leadership and continued support at the 7th Annual Interfaith Ramadan Dinner held on May 31st 2018 at the Royal Albert Palace in Edison, New Jersey.

The American Muslim Council of New Jersey (AMC) is a non-profit organization based in New Jersey with a message of peace and unity to people of diverse backgrounds and Interfaith community. The dinner was attended by over 700 guests and other honorees included Senator Robert Menendez; Attorney General Gurbir Grewal; New Jersey Commissioner of Health Mr. Shereef El Nahal; Chief of Staff at New Jersey General Assembly Mr. Shariq Ahmad and Dr. Dalia Fahmy an associate professor at Long Island University

In his acceptance speech, Mr. Naeem thanked the American Muslim Council for the recognition and stated “I am honored to be a part of such a prestigious group of recipients. I commend AMC for creating a forum for continued interfaith dialogue, it is indeed a need of the hour”.

About Sunrise Second Chance Foundation Inc.

Sunrise Second Chance FoundationSM (SSCF) is a privately held charity organization founded in 2015 by Mr. Mohammad Naeem in Irvington, New Jersey and incorporated in 2018.

The Foundation focuses its resources and energy on developing and administering “grassroots community-based programs”. We address addictions broadly and “Opioids” specifically. Our programs are geared towards Education, Prevention and Treatment for those suffering from substance abuse in order to help rebuild their lives and overcome addiction. We offer Direct Services, Community Programs and partner with institutions and policymakers to change the way the world fights opioid addiction.

This press release contains forward-looking statements including with respect to estimated 2018 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements.

Read more
Mohammad Naeem is a philanthropist, serial entrepreneur and a strategist.

Mail form

    Contacts

    © Mohammed Naeem 2025 - All Rights Reserves